Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Minipigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Minipigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

Outlook’s Lytenava Gets CRL for Manufacturing Issues, More Evidence

  • Post author:PacConAdmin
  • Post published:August 31, 2023
  • Post category:Uncategorized

The FDA issued Outlook Therapeutics a complete response letter (CRL) on its BLA for Lytenava (bevacizumab), an investigational ophthalmic formulation under development to treat wet age-related macular degeneration (AMD). Source:…

Continue ReadingOutlook’s Lytenava Gets CRL for Manufacturing Issues, More Evidence

Companies Regulated by CDRH Near Top of FDA Ombudsman’s Frequent Flyer List

  • Post author:PacConAdmin
  • Post published:August 30, 2023
  • Post category:Uncategorized

After inquiries about food, the FDA Office of the Ombudsman hears most often from device companies — because there are more small companies in that area of the industry —…

Continue ReadingCompanies Regulated by CDRH Near Top of FDA Ombudsman’s Frequent Flyer List

Novo Nordisk Buys Another Obesity Drugmaker as Wegovy Fever Continues to Rise

  • Post author:PacConAdmin
  • Post published:August 30, 2023
  • Post category:Uncategorized

Novo Nordisk has acquired Embark Biotech, as the larger Danish drugmaker looks to expand its blockbuster obesity drug portfolio in the wake of surging economic demand and rising market shortages…

Continue ReadingNovo Nordisk Buys Another Obesity Drugmaker as Wegovy Fever Continues to Rise

Quick Notes for Aug. 30, 2023

  • Post author:PacConAdmin
  • Post published:August 30, 2023
  • Post category:Uncategorized

Our coverage spans a bone graft product that caused a tuberculosis infection, a subcutaneous cancer treatment, a warning letter for an eye drop manufacturer, 300 higher risk patients with a…

Continue ReadingQuick Notes for Aug. 30, 2023

Three FDA Guidances: Using Real-World Data in Observational Studies and DSCSA

  • Post author:PacConAdmin
  • Post published:August 30, 2023
  • Post category:Uncategorized

The FDA issued three final guidances on Wednesday, one on the use of real-world data (RWD) in noninterventional (observational) studies and two on the Drug Supply Chain Security Act (DSCSA).…

Continue ReadingThree FDA Guidances: Using Real-World Data in Observational Studies and DSCSA

Meeting Planner — Week of Aug. 28, 2023

  • Post author:PacConAdmin
  • Post published:August 30, 2023
  • Post category:Uncategorized

Upcoming events in the coming weeks include ten FDA advisory committee meetings as well as the GMP Quality Management vSummit, the WCG MAGI@Home Clinical Research Conference 2023, the 18th Annual…

Continue ReadingMeeting Planner — Week of Aug. 28, 2023

Drugmakers Voice Strong Opposition to Medicare Drug Price Negotiation List

  • Post author:PacConAdmin
  • Post published:August 29, 2023
  • Post category:Uncategorized

Pharmaceutical companies directly impacted by HHS’ Tuesday announcement of the initial 10 drugs slated for Medicare price negotiations via the Inflation Reduction Act (IRA) have swiftly reacted, with many of…

Continue ReadingDrugmakers Voice Strong Opposition to Medicare Drug Price Negotiation List

FTC and DOJ Host Workshop on New Merger Guidelines

  • Post author:PacConAdmin
  • Post published:August 29, 2023
  • Post category:Uncategorized

The FTC and the Department of Justice (DOJ) will co-host a Sept. 5 workshop on draft merger guidelines the agencies propose to use when assessing whether a merger may violate…

Continue ReadingFTC and DOJ Host Workshop on New Merger Guidelines

Ethylene Oxide Consent Decree Means EPA Must Complete Work by March 2024

  • Post author:PacConAdmin
  • Post published:August 29, 2023
  • Post category:Uncategorized

The Environmental Protection Agency (EPA) must complete its work on the final rule governing commercial sterilization using ethylene oxide (EtO) by March 1, 2024, following the government’s signature on a…

Continue ReadingEthylene Oxide Consent Decree Means EPA Must Complete Work by March 2024

FDA Inspection Shows Fisher Wallace Failed to Report Serious Adverse Events

  • Post author:PacConAdmin
  • Post published:August 29, 2023
  • Post category:Uncategorized

Despite customers’ reporting symptoms that included stroke, memory loss, atrial ffibrillation, bradycardia and seizures after using Fisher Wallace Labs’ at-home electroconvulsive therapy (ECT) device, the company did not submit the…

Continue ReadingFDA Inspection Shows Fisher Wallace Failed to Report Serious Adverse Events
  • Go to the previous page
  • 1
  • …
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • …
  • 328
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:
6042 Cornerstone Court W
Suite E
San Diego, CA 92121
Social::
© 2025 BioLegacy Research. All rights reserved.
BioLegacy research is a PharmaLegacy Laboratories company